Mode
Text Size
Log in / Sign up

Mirabegron and onabotulinumtoxinA reduce urinary frequency and nocturia in patients with Parkinson's disease and overactive bladderNew data shows mirabegron and Botox help Parkinson's bladder issues

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that mirabegron and BoNT-A reduce urinary frequency and nocturia in Parkinson's patients with overactive bladder.

This meta-analysis synthesizes data regarding the use of mirabegron and intradetrusor onabotulinumtoxinA (BoNT-A) for managing overactive bladder in adults with idiopathic Parkinson's disease. The analysis focused on primary outcomes including 24-h voiding frequency, nocturia, urgency, and incontinence, alongside secondary outcomes such as postvoid residual (PVR) volume.

Key findings include a reduction in 24-h urinary frequency (MD -4.48; 95% CI -8.45 to -0.52) and nocturia (MD -1.36; 95% CI -2.68 to -0.05). Incontinence also showed a reduction (MD -1.24; 95% CI -1.98 to -0.50). While urgency showed a reduction (MD -2.68), the result did not reach statistical significance (95% CI -7.08 to 1.72). Regarding PVR, BoNT-A was associated with an increase of 43 mL, while mirabegron showed a minimal change of 3 mL.

The authors note several limitations, including the absence of direct head-to-head comparative trials, small sample sizes, heterogeneity, and short follow-up periods. Due to these factors, the evidence is of low to moderate certainty. The findings are currently considered hypothesis-generating for the management of overactive bladder in this specific population.

How this fits prior evidence

This meta-analysis addresses a gap in managing overactive bladder specifically within the Parkinson's disease population. While previous coverage has identified neural correlates for freezing of gait and the impact of gut microbiota on neuroinflammation in Parkinson's disease, this study focuses on the pharmacological and procedural management of comorbid urinary symptoms.

Living with Parkinson's disease can bring many challenges, including an overactive bladder. This condition often leads to frequent trips to the bathroom and a sudden, uncontrollable urge to go, which can disrupt daily life and sleep. New data suggests that two specific treatments, mirabern and a type of Botox injection, may help manage these symptoms.

Researchers looked at how these treatments worked for adults with Parkinson's and overactive bladders. The results showed that mirabegron helped reduce how often people had to urinate during the day and decreased the number of times they had to get up at night. The Botox injections also helped reduce the number of times people experienced a sudden urge to go and lowered instances of bladder leakage.

While these results are promising, the evidence is still early. The study notes that some results, like the reduction in urgency, were not statistically significant. Additionally, the study had small sample sizes and lacked a direct head-to-head comparison between the two treatments. Mirabegron was generally well tolerated, though it can cause mild side effects like dizziness or constipation. Talk to your doctor to see if these options fit your specific needs.

What this means for you:
Mirabegron and Botox injections can reduce frequent urination and bladder urgency in people with Parkinson's.

Common questions

How do these treatments help with bladder issues?

Mirabegron can reduce how often you need to urinate during the day and decrease nighttime bathroom trips. Botox injections, known as onabotulinumtoxinA, can help reduce the sudden urge to go and decrease instances of bladder leakage for people with Parkinson's disease.

Are there side effects to these medications?

Mirabegron is generally well tolerated, but it can cause mild side effects like dizziness, constipation, or high blood pressure. The Botox injection may cause a temporary delay in emptying the bladder or a urinary tract infection.

Is this treatment proven for everyone with Parkinson's?

The findings are currently used to generate new ideas for treatment rather than providing a definitive rule. Because the study had small sample sizes and lacked a direct head-to-head comparison, you should talk to your doctor about your specific situation.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
OBJECTIVE: To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT-A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). METHODS: A systematic review and meta-analysis with parallel synthesis of two distinct interventions was conducted of randomized and observational studies involving adults with idiopathic PD and OAB treated with mirabegron or BoNT-A. Primary outcomes included mean change in 24-h voiding frequency, nocturia, urgency, and incontinence. Secondary outcomes were postvoid residual (PVR) volume and adverse events. Pooled outcomes were reported as mean differences (MDs), representing the change in symptoms from baseline to follow-up; negative MDs indicate a reduction in symptom frequency. RESULTS: No direct head-to-head comparative trials of mirabegron versus BoNT-A were identified; however, eight single-arm pre-post studies met the inclusion criteria. Pooled analysis showed reductions in 24-h urinary frequency (MD -4.48; 95% CI -8.45 to -0.52), nocturia (MD -1.36; 95% CI -2.68 to -0.05), urgency (MD -2.68; 95% CI -7.08 to 1.72), and incontinence (MD -1.24; 95% CI -1.98 to -0.50). BoNT-A was associated with a mean increase in PVR (+43 mL), whereas mirabegron was associated with minimal change (+3 mL). Adverse events were generally mild with mirabegron (e.g., dizziness, constipation, hypertension), whereas BoNT-A was associated with transient urinary retention and urinary tract infection. The certainty of evidence across outcomes was low to moderate and therefore should be interpreted with caution. CONCLUSION: Currently, no studies have directly compared the benefits of mirabegron versus BoNT-A. Available study data confirm that both mirabegron and BoNT-A were associated with directional reductions in several OAB symptoms in PD. However, urgency and most subgroup analyses did not reach statistical significance. The overall certainty of evidence was low to moderate due to small sample sizes, heterogeneity, and short follow-up. These findings are hypothesis-generating and should be confirmed in larger, randomized controlled trials with longer follow-up and ideally comparing effects head-to-head. PROSPERO Registration: CRD420251181682.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.